The melanocortin-4 receptor pathway and the emergence of precision medicine in obesity management.

antiobesity drug appetite control effectiveness obesity therapy

Journal

Diabetes, obesity & metabolism

ISSN: 1463-1326

Titre abrégé: Diabetes Obes Metab

Pays: England

ID NLM: 100883645

Informations de publication

Date de publication:
19 Mar 2024

Historique:

revised: 15 02 2024

received: 21 12 2023

accepted: 29 02 2024

medline: 20 3 2024

pubmed: 20 3 2024

entrez: 20 3 2024

Statut: aheadofprint

Résumé

Over the past few decades, there has been a global surge in the prevalence of obesity, rendering it a globally recognized epidemic. Contrary to simply being a medical condition, obesity is an intricate disease with a multifactorial aetiology. Understanding the precise cause of obesity remains a challenge; nevertheless, there seems to be a complex interplay among biological, psychosocial and behavioural factors. Studies on the genetic factors of obesity have revealed several pathways in the brain that play a crucial role in food intake regulation. The best characterized pathway, thus far, is the leptin-melanocortin pathway, from which disruptions are responsible for the majority of monogenic obesity disorders. The effectiveness of conservative lifestyle interventions in addressing monogenic obesity has been limited. Therefore, it is crucial to complement the management strategy with pharmacological and surgical options. Emphasis has been placed on developing drugs aimed at replacing the absent signals, with the goal of restoring the pathway. In both monogenic and polygenic forms of obesity, outcomes differ across various interventions, likely due to the multifaceted nature of the disease. This underscores the need to explore alternative therapeutic strategies that can mitigate this heterogeneity. Precision medicine can be regarded as a powerful tool that can address this concern, as it values the understanding of the underlying abnormality triggering the disease and provides a tailored treatment accordingly. This would assist in optimizing outcomes of the current therapeutic approaches and even aid in the development of novel treatments capable of more effectively managing the global obesity epidemic.

Identifiants

DOI: 10.1111/dom.15555 PMID: 38504134

pubmed: 38504134

doi: 10.1111/dom.15555

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : NIH HHS

ID : NIH K23-DK114460

Pays : United States

Informations de copyright

Références

Ataey A, Jafarvand E, Adham D, Moradi-Asl E. The relationship between obesity, overweight, and the human development index in World Health Organization eastern Mediterranean region countries. J Prev Med Public Health. 2020;53(2):98-105.

Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(3):254-266.

Rosen H. Is obesity a disease or a behavior abnormality? Did the AMA get it right? Mo Med. 2014;111(2):104-108.

Hill JJ. Obesity: an emerging threat. J Natl Black Nurses Assoc. 2018;29(2):36-39.

Acosta A, Streett S, Kroh MD, et al. White paper AGA: POWER - practice guide on obesity and weight management, education, and resources. Clin Gastroenterol Hepatol. 2017;15(5):631-649.e10.

Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22(7 Suppl):s176-s185.

Hurtado AM, Acosta A. Precision medicine and obesity. Gastroenterol Clin North Am. 2021;50(1):127-139.

Jackson VM, Breen DM, Fortin JP, et al. Latest approaches for the treatment of obesity. Expert Opin Drug Discovery. 2015;10(8):825-839.

Kadouh HC, Acosta A. Current paradigms in the etiology of obesity. Tech Gastrointest Endosc. 2017;19(1):2-11.

Lotta LA, Mokrosiński J, Mendes de Oliveira E, et al. Human gain-of-function MC4R variants show signaling bias and protect against obesity. Cell. 2019;177(3):597-607.e9.

Baldini G, Phelan KD. The melanocortin pathway and control of appetite-progress and therapeutic implications. J Endocrinol. 2019;241(1):R1-r33.

Li G, Hu Y, Zhang W, et al. Brain functional and structural magnetic resonance imaging of obesity and weight loss interventions. Mol Psychiatry. 2023;28(4):1466-1479.

Ferrulli A, Macrì C, Terruzzi I, et al. Weight loss induced by deep transcranial magnetic stimulation in obesity: a randomized, double-blind, sham-controlled study. Diabetes Obes Metab. 2019;21(8):1849-1860.

Cifuentes L, Hurtado AMD, Eckel-Passow J, Acosta A. Precision medicine for obesity. Dig Dis Interv. 2021;5(3):239-248.

Acosta A, Camilleri M, Abu Dayyeh B, et al. Selection of Antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662-671.

Seidell JC, Flegal KM. Assessing obesity: classification and epidemiology. Br Med Bull. 1997;53(2):238-252.

Health implications of obesity. National Institutes of Health consensus development conference Statement. Ann Intern Med. 1985;103(1):147-151.

Weir CB, Jan A. BMI Classification Percentile And Cut Off Points, in StatPearls. 2023 StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Arif Jan declares no relevant financial relationships with ineligible companies.

Caballero B. Humans against obesity: who will win? Adv Nutr. 2019;10(suppl_1):S4-s9.

Segal KR, Gutin B, Presta E, Wang J, van Itallie TB. Estimation of human body composition by electrical impedance methods: a comparative study. J Appl Physiol. 1985;58(5):1565-1571.

Vidwans HB, Watve MG. How much variance in insulin resistance is explained by obesity? J. Insulin Resist. 2017;2(1):1-7.

Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10(3):207-215.

Yusuf S, Hawken S, Ôunpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640-1649.

Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab study. Int J Obes Relat Metab Disord. 2004;28(3):402-409.

Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019;92:51-60.

Bell JA, Hamer M, Batty GD, Singh-Manoux A, Sabia S, Kivimäki M. Incidence of metabolic risk factors among healthy obese adults: 20-year follow-up. J Am Coll Cardiol. 2015;66(7):871-873.

van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.

Blüher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):bnaa004.

Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev. 2019;20(6):816-828.

Acosta A, Camilleri M, Shin A, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology. 2015;148(3):537-546.e4.

Cifuentes L, Ghusn W, Feris F, et al. Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study. EClinicalMedicine. 2023;58:101923.

Hurtado MD, Cifuentes L, Campos A, et al. Sex as an independent variable in the measurement of satiation: a retrospective cohort study. Int J Obes (Lond). 2022;46(12):2156-2162.

Chial HJ, Camilleri C, Delgado-Aros S, et al. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil. 2002;14(3):249-253.

Blundell J, de Graaf C, Hulshof T, et al. Appetite control: methodological aspects of the evaluation of foods. Obes Rev. 2010;11(3):251-270.

Czepczor-Bernat K, Brytek-Matera A, Gramaglia C, Zeppegno P. The moderating effects of mindful eating on the relationship between emotional functioning and eating styles in overweight and obese women. Eat Weight Disord. 2020;25(4):841-849.

Dakanalis A, Mentzelou M, Papadopoulou SK, et al. The Association of Emotional Eating with overweight/obesity, depression, anxiety/stress, and dietary patterns: a review of the current clinical evidence. Nutrients. 2023;15(5).

Konttinen H. Emotional eating and obesity in adults: the role of depression, sleep and genes. Proc Nutr Soc. 2020;79(3):283-289.

Cifuentes L, Campos A, Silgado MLR, et al. Association between anxiety and eating behaviors in patients with obesity. Obes Pillars. 2022;3:100021.

Magyar ÉE, Csábi G, Tényi T, Tényi D. Yale food addiction scale - review of literature. Psychiatr Hung. 2016;31(3):256-260.

Arnow B, Kenardy J, Agras WS. The emotional eating scale: the development of a measure to assess coping with negative affect by eating. Int J Eat Disord. 1995;18(1):79-90.

Arhire LI, Niță O, Popa AD, et al. Validation of the Dutch eating behavior questionnaire in a Romanian adult population. Nutrients. 2021;13(11).

van Strien T. Causes of emotional eating and matched treatment of obesity. Curr Diab Rep. 2018;18(6):35.

Devonport TJ, Nicholls W, Fullerton C. A systematic review of the association between emotions and eating behaviour in normal and overweight adult populations. J Health Psychol. 2019;24(1):3-24.

Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33(3):289-295.

Marenne G, Hendricks AE, Perdikari A, et al. Exome sequencing identifies genes and gene sets contributing to severe childhood obesity, linking PHIP variants to repressed POMC transcription. Cell Metab. 2020;31(6):1107-1119.e12.

Clément K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960-970.

Pritchard LE, Turnbull AV, White A. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity. J Endocrinol. 2002;172(3):411-421.

Tolson KP, Gemelli T, Gautron L, Elmquist JK, Zinn AR, Kublaoui BM. Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and oxytocin expression. J Neurosci. 2010;30(10):3803-3812.

Hinney A, Vogel CI, Hebebrand J. From monogenic to polygenic obesity: recent advances. Eur Child Adolesc Psychiatry. 2010;19(3):297-310.

Clément K. Genetics of human obesity. C R Biol. 2006;329(8):608-622.

Singh RK, Kumar P, Mahalingam K. Molecular genetics of human obesity: a comprehensive review. C R Biol. 2017;340(2):87-108.

Ochoa MC, Marti A, Azcona C, et al. Gene-gene interaction between PPARγ2 and ADRβ3 increases obesity risk in children and adolescents. Int J Obes (Lond). 2004;28(3):S37-S41.

Chung WK. An overview of mongenic and syndromic obesities in humans. Pediatr Blood Cancer. 2012;58(1):122-128.

Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet. 1997;27(4):325-351.

Loos RJF, Janssens A. Predicting polygenic obesity using genetic information. Cell Metab. 2017;25(3):535-543.

Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocrinol. 2018;6(3):223-236.

Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120-133.

Chagnon YC, Rankinen T, Snyder EE, Weisnagel SJ, Pérusse L, Bouchard C. The human obesity gene map: the 2002 update. Obes Res. 2003;11(3):313-367.

Friedman JM. A war on obesity, not the obese. Science. 2003;299(5608):856-858.

Rao KR, Lal N, Giridharan NV. Genetic & epigenetic approach to human obesity. Indian J Med Res. 2014;140(5):589-603.

Mahmoud R, Kimonis V, Butler MG. Genetics of obesity in humans: a clinical review. Int J Mol Sci. 2022;23(19):e122011.

Yeo GSH, Chao DHM, Siegert AM, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy. Mol Metab. 2021;48:101206.

Obradovic M, Sudar-Milovanovic E, Soskic S, et al. Leptin and obesity: role and clinical implication. Front Endocrinol (Lausanne). 2021;12:585887.

Couce ME, Burguera B, Parisi JE, Jensen MD, Lloyd RV. Localization of leptin receptor in the human brain. Neuroendocrinology. 1997;66(3):145-150.

Morrison CD. Leptin signaling in brain: a link between nutrition and cognition? Biochim Biophys Acta. 2009;1792(5):401-408.

Lavoie O, Michael NJ, Caron A. A critical update on the leptin-melanocortin system. J Neurochem. 2023;165(4):467-486.

Siljee JE, Unmehopa UA, Kalsbeek A, Swaab DF, Fliers E, Alkemade A. Melanocortin 4 receptor distribution in the human hypothalamus. Eur J Endocrinol. 2013;168(3):361-369.

Wei R, Li D, Jia S, Chen Y, Wang J. MC4R in central and peripheral systems. Adv Biol (Weinh). 2023;7(9):2300035.

Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124(10):4223-4226.

Farooqi IS, Keogh JM, Yeo GSH, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348(12):1085-1095.

da Fonseca ACP, Abreu GM, Zembrzuski VM, et al. Identification of the MC4R start lost mutation in a morbidly obese Brazilian patient. Diabetes Metab Syndr Obes. 2019;12:257-266.

Hinney A, Bettecken T, Tarnow P, et al. Prevalence, spectrum, and functional characterization of melanocortin-4 receptor gene mutations in a representative population-based sample and obese adults from Germany. J Clin Endocrinol Metab. 2006;91(5):1761-1769.

MacKenzie RG. Obesity-associated mutations in the human melanocortin-4 receptor gene. Peptides. 2006;27(2):395-403.

Stutzmann F, Tan K, Vatin V, et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes. 2008;57(9):2511-2518.

Lubrano-Berthelier C, Dubern B, Lacorte JM, et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab. 2006;91(5):1811-1818.

Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet. 1998;20(2):111-112.

Panaro BL, Tough IR, Engelstoft MS, et al. The Melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in Vivo. Cell Metab. 2014;20(6):1018-1029.

Gantz I, Konda Y, Tashiro T, et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem. 1993;268(11):8246-8250.

Niu J, Tong J, Blevins JE. Oxytocin as an anti-obesity treatment. Front Neurosci. 2021;15:743546.

Semple E, Shalabi F, Hill JW. Oxytocin neurons enable melanocortin regulation of male sexual function in mice. Mol Neurobiol. 2019;56(9):6310-6323.

McCormack SE, Blevins JE, Lawson EA. Metabolic effects of oxytocin. Endocr Rev. 2019;41(2):121-145.

Tyrrell J, Wood AR, Ames RM, et al. Gene-obesogenic environment interactions in the UK biobank study. Int J Epidemiol. 2017;46(2):559-575.

Sacoto D, Hurtado MD, Acosta A. Precision medicine and obesity. Handb Exp Pharmacol. 2022;274:467-485.

Fenech M, el-Sohemy A, Cahill L, et al. Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice. J Nutrigenet Nutrigenomics. 2011;4(2):69-89.

Qi Q, Chu AY, Kang JH, et al. Fried food consumption, genetic risk, and body mass index: gene-diet interaction analysis in three US cohort studies. BMJ. 2014;348:g1610.

Madkour MI, Malhab LJB, Abdel-Rahman WM, Abdelrahim DN, Saber-Ayad M, Faris ME. Ramadan diurnal intermittent fasting is associated with attenuated FTO gene expression in subjects with overweight and obesity: a prospective cohort study. Front Nutr. 2021;8:741811.

Leońska-Duniec A, Cięszczyk P, Ahmetov II. Chapter eleven - genes and individual responsiveness to exercise-induced fat loss. In: Barh D, Ahmetov II, eds. Sports, Exercise, and Nutritional Genomics. Academic Press; 2019:231-247.

Kilpeläinen TO, Qi L, Brage S, et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011;8(11):e1001116.

Cauchi S, Stutzmann F, Cavalcanti-Proença C, et al. Combined effects of MC4R and FTO common genetic variants on obesity in European general populations. J Mol Med. 2009;87(5):537-546.

Keller MC. Gene × environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. Biol Psychiatry. 2014;75(1):18-24.

Trapp CM, Censani M. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity. Curr Opin Endocrinol Diabetes Obes. 2023;30(2):136-140.

Reinehr T, Hebebrand J, Friedel S, et al. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. Obesity (Silver Spring). 2009;17(2):382-389.

Hainerová I, Larsen LH, Holst B, et al. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. J Clin Endocrinol Metab. 2007;92(9):3689-3696.

Trier C, Hollensted M, Schnurr TM, et al. Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 receptor mutations. Int J Obes (Lond). 2021;45(1):66-76.

Farooqi IS, O'Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol. 2014;223(1):T63-T70.

Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. Metabolism. 2015;64(1):146-156.

Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science. 2007;317(5843):1355.

Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879-884.

Clément K, Biebermann H, Farooqi IS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551-555.

Kühnen P, Clément K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a Melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240-246.

Kühnen P, Clément K. Long-term MC4R agonist treatment in POMC-deficient patients. N Engl J Med. 2022;387(9):852-854.

Collet TH, Dubern B, Mokrosinski J, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321-1329.

Chen KY, Muniyappa R, Abel BS, et al. RM-493, a Melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metabol. 2015;100(4):1639-1645.

Krishna R. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009;86(6):659-666.

Royalty JE, Konradsen G, Eskerod O, Wulff BS, Hansen BS. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects. J Clin Pharmacol. 2014;54(4):394-404.

Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials. Diabetes Obes Metab. 2022;24(6):1084-1093.

Kühnen P, Wiegand S, Biebermann H. Pharmacological treatment strategies for patients with monogenic obesity. J Pediatr Endocrinol Metab. 2020;33:967-973.

Markham A. Setmelanotide: First Approval. Drugs. 2021;81(3):397-403.

Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411(6836):480-484.

René P, le Gouill C, Pogozheva ID, et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther. 2010;335(3):520-532.

Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev. 2010;31(4):506-543.

Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360(1):44-52.

Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013;62(2):490-497.

Iepsen EW, Zhang J, Thomsen HS, et al. Patients with obesity caused by Melanocortin-4 receptor mutations can Be treated with a glucagon-like Peptide-1 receptor agonist. Cell Metab. 2018;28(1):23-32.e3.

Lawson EA. The effects of oxytocin on eating behaviour and metabolism in humans. Nat Rev Endocrinol. 2017;13(12):700-709.

Lawson EA, Marengi DA, DeSanti RL, Holmes TM, Schoenfeld DA, Tolley CJ. Oxytocin reduces caloric intake in men. Obesity (Silver Spring). 2015;23(5):950-956.

Hsu EA, Miller JL, Perez FA, Roth CL. Oxytocin and naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection. J Clin Endocrinol Metab. 2018;103(2):370-375.

Vos N, Oussaada SM, Cooiman MI, et al. Bariatric surgery for monogenic non-syndromic and syndromic obesity disorders. Curr Diab Rep. 2020;20(9):44.

Censani M, Conroy R, Deng L, et al. Weight loss after bariatric surgery in morbidly obese adolescents with MC4R mutations. Obesity (Silver Spring). 2014;22(1):225-231.

Tas A, Atabey M, Gokcen P, et al. Leptin/melanocortin pathway hormones in obese patients after laparoscopic sleeve gastrectomy. Eur Rev Med Pharmacol Sci. 2022;26(5):1484-1491.

Poitou C, Puder L, Dubern B, et al. Long-term outcomes of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR, and MC4R genes. Surg Obes Relat Dis. 2021;17(8):1449-1456.

Campos A, Cifuentes L, Hashem A, et al. Effects of heterozygous variants in the leptin-melanocortin pathway on roux-en-Y gastric bypass outcomes: a 15-year case-control study. Obes Surg. 2022;32(8):2632-2640.

Anazco D, Ghusn W, Campos A, et al. Type 2 diabetes remission in patients with heterozygous variants in the leptin-melanocortin pathway after roux-en-Y gastric bypass: a matched case-control study. Obes Surg. 2023;33(11):3502-3509.

Gala K, Ghusn W, Fansa S, et al. Effects of heterozygous variants in the leptin-melanocortin pathway on transoral outlet reduction after roux-en-Y gastric bypass: a case-control study and review of literature. Obes Surg. 2023;33(4):1284-1288.

Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci. 2016;130(12):943-986.

Ranadive SA, Vaisse C. Lessons from extreme human obesity: monogenic disorders. Endocrinol Metab Clin North Am. 2008;37(3):733-751.

Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. Jama. 2014;312(9):923-933.

Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3-14.

Ghusn W, de la Rosa A, Sacoto D, et al. Weight loss outcomes associated with Semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022;5(9):e2231982.

O'Brien PE, Hindle A, Brennan L, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-Centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29(1):3-14.

Del Corral P, Chandler-Laney PC, Casazza K, Gower BA, Hunter GR. Effect of dietary adherence with or without exercise on weight loss: a mechanistic approach to a global problem. J Clin Endocrinol Metab. 2009;94(5):1602-1607.

Fujioka K, O'Neil PM, Davies M, et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring). 2016;24(11):2278-2288.

MacLean PS, Rothman AJ, Nicastro HL, et al. The accumulating data to optimally predict obesity treatment (ADOPT) Core measures project: rationale and approach. Obesity (Silver Spring). 2018;26 Suppl 2(Suppl 2):S6-s15.

Chami N, Preuss M, Walker RW, Moscati A, Loos RJF. The role of polygenic susceptibility to obesity among carriers of pathogenic mutations in MC4R in the UK biobank population. PLoS Med. 2020;17(7):e1003196.

Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean AdultsA randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568-1575.

Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197-206.

Hung CF, Breen G, Czamara D, et al. A genetic risk score combining 32 SNPs is associated with body mass index and improves obesity prediction in people with major depressive disorder. BMC Med. 2015;13:86.

Khera AV, Chaffin M, Wade KH, et al. Polygenic prediction of weight and obesity trajectories from birth to adulthood. Cell. 2019;177(3):587-596.e9.

de Toro-Martín J, Guénard F, Tchernof A, Pérusse L, Marceau S, Vohl MC. Polygenic risk score for predicting weight loss after bariatric surgery. JCI Insight. 2018;3(17):e122011.

Katsareli EA, Amerikanou C, Rouskas K, et al. A genetic risk score for the estimation of weight loss after bariatric surgery. Obes Surg. 2020;30(4):1482-1490.